Investigators said that the OLE study showed Roche’s gantenerumab dropped the risk of developing Alzheimer's symptoms by 50%.

Roche has acquired rights to an obesity therapy by Denmark's Zealand Pharma in a collaboration deal worth up to $5.3 billion, ...

Roche moved to enter the booming weight-loss drug market now dominated by Novo Nordisk and Eli Lilly. The Swiss ...

The deal gives the Swiss pharma access to an experimental amylin-targeting treatment it will test in combination with drugs ...

Swiss pharmaceutical giant Roche said Wednesday that it had struck a deal worth up to $5.3 billion to develop Zealand ...

Roche’s up to $1 billion investment will provide access to Oxford BioTherapeutics’ antibody-drug conjugate platform for ...

Over the past few days, as the rest of the stock market melted down, a revolution has been quietly brewing in the market for ...

The FDA wants to end bulk production of copycat versions of weight loss drugs; telehealth companies and compounding ...

Roche shares gained 5.5%. Zealand is testing petrelintide, opens new tab in overweight or obese individuals without type 2 diabetes in a mid-stage study. Petrelintide belongs to a class of drugs ...

A long-term human trial has found that a discontinued drug halved the presentation of early-onset Alzheimer's disease in ...

Germany's financial markets watchdog is looking at whether Bayer fairly disclosed plans for shareholder approval of a capital ...

Acne creams from retailers including Walgreens, La Roche-Posay and Proactiv have been voluntarily recalled due to elevated ...